About: http://data.cimple.eu/news-article/4a2d811cc49d62201f8a034421bd5dedf863a7e661579da333bda152

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/4a2d811cc49d62201f8a034421bd5dedf863a7e661579da333bda152 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	The United States on Monday approved a drug called Aduhelm to treat patients with Alzheimer's, the first new medicine against the disease in almost two decades and the first to address cognitive decline linked to the condition. The decision was highly anticipated but also contentious, because an independent expert panel convened by the regulatory Food and Drug Administration last November found insufficient evidence of Aduhelm's benefit. "Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer's disease, the presence of amyloid beta plaques in the brain," said the FDA's Patrizia Cavazzoni. Nevertheless, the decision falls under the FDA's "Accelerated Approval" pathway which it uses when it believes a medicine may provide meaningful benefit over existing treatments but there is still some uncertainty. "As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives," said Cavazzoni in a statement acknowledging the controversy. Aduhelm, a monoclonal antibody also known by its generic name aducanumab, was tested in two late-stage human trials known as Phase 3 trials. It showed a reduction in cognitive decline in one, but not the other. But in all studies, it convincingly showed a reduction in the build-up of a protein called beta-amyloid in the brain tissue of Alzheimer's patients. One theory holds that Alzheimer's disease comes from an excessive accumulation of these proteins in some people's brains as they age and their immune systems decline. Providing such patients antibodies could therefore be a means to restore some of their capacity to clear the plaque build-up. The last Alzheimer's drug was approved in 2003, and all previous medicines have targteted symptoms associated with the disease, not its underlying cause. Alzheimer's, the most common form of dementia, is thought to affect 50 million people worldwide and usually starts over the age of 65. It progressively destroys brain tissue, robbing people of their memory, leaving them disoriented and at times unable to carry out everyday tasks. It's also associated with dramatic mood swings and trouble communicating. ia/bfm
schema:headline	US approves first new Alzheimer's drug in almost two decades
schema:mentions	Memory Medication Protein Ia (cuneiform) Dementia Brain Food and Drug Administration United States Aducanumab Amyloid beta Pathophysiology Cognitive deficit Accelerated approval (FDA) Monoclonal antibody Radio in New Zealand
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-06-07 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	83 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software